Election

U.S. Serial No. 09/4

Atty Reference: 037003-0275478

Page 2

ユロレビIVED

SEP 0 6 2001

TECH CENTER 1600/2900

Further to the response to the previous Official Action filed April 16, 2001, Applicants confirm the election of Group B directed to use of an anti-CD40L specific antibody in combination with anti-CD20 specific antibody as the elected species. Applicants further elect leukemia as the CD40+ malignancy, 90Y as the radiolabel and alkylating agents as the chemotherapeutics to be searched in combination with the elected species. It is assumed that this requirement is only for purposes of examination and that the Examiner will extend the search to other species upon a determination that the elected combination is patentable.

New claims 57-59 are based on the claims and specification as originally filed and recite embodiments that read on the elected species.

If the Examiner has any questions in connection with this election, he should contact the undersigned so that prosecution may be expedited.

In view of the foregoing, the claims are now believed to be in form for allowance, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

All objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

A supplemental Declaration is also enclosed herein.

Applicants hereby petition for an extension of time of one (1) month for responding to the outstanding Office Action of July 3, 2001. A check in the amount of \$110 is enclosed herein.

Respectfully submitted,

Pillsbury Winthrop LLP

By:

ir Elamrani

Registration No. 43,601

1600 Tysons Boulevard, Suite 100 McLean, Virginia 22102 (703) 905-2000

(703) 905-2500 Facsimile

Date: September 4 2001